The Latest Breaking News from biotechnology

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Genetically modified (GM) cowpea has cleared the first of the three regulatory hurdles in the way of commercialisation in Ghana. If it is commercialised, it will be the first GM crop grown in the country – a major milestone. Biotechnology proponents have been working for decades to integrate GM crops…

Holds roadshow in city on its new Biotechnology Policy  

Vir Biotechnology Inc shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Tisco Bank's wealth advisory unit suggests moving away from energy stocks to biotechnology and healthcare as several US economic indicators have signalled a higher risk of recession.

Nigeria – the sixth largest producer of cashew nuts globally – exports more than 80% of its raw cashews primarily to Vietman and India where they are processed into various consumer products such as butter, food and cosmetic ingredients.

Wood also dumped a familiar biotechnology name, and bought two other stocks for the second day in a row.

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…